Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

PSB to co-ordinate Industrial-Academic Partnership programme (Transvac) in international biomedical portfolio management

14.11.2006
Fondazione Parco Biomedico San Raffaele is to co-ordinate the European commission Marie Curie Industry-Academia Partnership project ‘Transvac’ in International Biomedical Portfolio management.

Through the secondment of Business Development Managers in the participating centres Transvac aims to find an effective way to manage biomedical research alliances across the European continent and generate an active portfolio of projects with high potential for creating knowledge and value which will be actively managed. Specifically it aims to develop a pipeline of portfolio projects that are actively managed and supported between the centres classified as:

-Fundamental research or clinical projects based on existing R&D synergies and projects
or
- Applied industrial research projects based on existing R&D synergies and projects to significantly advance the development of a potential revenue generating product

Effort will be focused on regenerative therapies and research in musculo-skeletal, cardiological and neurological disorders, utilising the expertise and insights of the participants in cell therapies, biopharmaceuticals and biomaterial/polymer and nano-based biopharmaceutical delivery to generate an early stage to pre-clinical/clinical phase I pipeline of projects.

Significant effort will be dedicated to the inclusion of SME’s in the applied industrial projects, as partners, customers for the intellectual property with the long-term aim of out-licensing the inventions to large industry.

Partners in the project are:

Fondazione Parco Biomedico San Raffaele (PSB)

Located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region. Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes. The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit.

The Cambridge University Centre for Brain Repair (http://www.brc.cam.ac.uk) contains 14 scientific groups, with research interests in stem cell biology, neurodegeneration, neuroprotection, demyelination, remyelination, axon regeneration, plasticity, neural transplantation, clinical neurology and neurosurgery. In axon regeneration there are two approaches. 1) Axon regeneration after CNS injury is blocked by the formation of a glial scar. The major inhibitory molecules in the glial scar are chondroitin sulphate proteoglycans. The group is studying methods of removing proteoglycans, preventing their synthesis and of modifying the scarring process to prevent the appearance of inhibitory molecules. 2) Adult CNS axons have a very poor intrinsic ability to regenerate their axons after damage which correlates with poor ability to regenerate the growth cone on the end of a cut axon. Growth cone regeneration requires new protein synthesis inside the axon at the site of axotomy. CNS axons lack protein synthesis machinery. Expertise in glial cell biology, axon growth assays, models of brain and spinal cord damage, behavioural assays of spinal cord and brain function, extra cellular matrix biochemistry, axonal transport and protein synthesis, time lapse studies of axon growth. Facilities for animal behavioural studies, lesion models, imaging, neurodegenerative conditions, neural transplantation, stem cell biology, clinical studies in Parkinsons disease, Huntingtons disease, multiple sclerosis, head injury, stroke, rehabilitation.

Dando & Colucci is a management company, specialising in facilitating the development, financing and implementation of life science based innovation ‘clusters’ or science parks by providing tailored insight and management, offering tactical and strategic management to permit correct financial management, leveraging of resources, positioning of clusters/parks on the whole value chain associated with research and development. This stretches from fundamental research through to partnering at the time of real value creation. As such their expertise includes: Internal due diligence to ISO 9001 quality standards; Consortium development and partner recruitment; Fund raising and identification of potential financial backers; Elaboration and negotiation of detailed scientific and development plan; Executive and project management; Consortium operational development and organisation; Resource and technical evaluation; Business development and market analysis; Financial co-ordination and reporting, and Intellectual property management co-ordination.

Centres working with Dando and Colucci LLC managers as part of the project are:

The Institute of Chemical Science and Engineering, EPFL Lausanne, (http://lmrp.epfl.ch/) works in regenerative medicine and pharmacobiology, specialises in chemical engineering polymeric biomaterials, in tissue engineering using stem cells as building blocks. DNA oligos, recombinant proteins and synthetic peptides are designed and expressed to encompass many functions: the ability to be chemically cross linked with an exogenous agent, the ability to be degraded by cell-derived proteases, the ability to support and promote cell migration, and the ability to bind to and slowly release growth factors. These materials are being developed as biosynthetic matrices and nano-vessicles for tissue regeneration. By virtue of the precise design that is possible, one may independently control the rates of cell infiltration, degradation, remodelling, etc., by making changes in the amino acid sequence of the protein polymer. In addition most degradable biomaterials degrade by non-enzymatic hydrolysis. This is in stark contrast to all natural biological degradation, which is precisely regulated by cell-derived proteases. Research facilities include cell biology, molecular biology and peptide and protein chemistry, organic and polymer synthesis, small animal surgery and pharmacology and a fully equipped laboratory for synthesis and characterization of organic polymeric biomaterials, including analytical and preparative HPLC, differential scanning calorimetry, FT-IR spectroscopy, mass spectrometry, rotary evaporators, UV/Vis spectroscopy, automated peptide synthesizer, photo documentation station, preparative FPLC, RT-PCR.

ECRIN (http://www.ecrin.org) is based on the interconnection of national networks of clinical research centres (CRCs) and clinical trial units (CTUs) the European Clinical Research Infrastructures Network (ECRIN) programme is designed to develop an infrastructure allowing for bottom-up harmonisation of support, training, and practice of clinical research. ECRIN aims at providing public or private (mainly biotechnology SME) sponsors with a support for translational research and multicentre clinical studies in Europe. The ECRIN consortium is based on national networks of CRC / CTUs together with the European Forum for Good Clinical Practice (EFGCP).

A major objective of ECRIN consists of stimulating and facilitating the creation of Centres and National Networks, especially in the new member states, for their subsequent connection to the European network. Connecting these national networks within a broad European network will contribute to the critical mass at the European level needed for the implement of European standards and training regarding clinical research. The European Consortium of clinical research infrastructures currently includes 8 networks of CRCs and CTUs, covering 6 European countries representing 260 million citizens (Denmark, France, Germany, Italy, Spain, and Sweden), and constituting 112 different medical centres and hospitals conducting 1500 clinical studies.

Jonathan Dando | alfa
Further information:
http://www.scienceparkrome.org

Further reports about: Axon Biology CRC Development ECRIN Regeneration cell biology synthesis

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>